Upcoming Webinar
Clinical Insights into the Management of mCSPC
Date: December 2, 2025 | 2:00 PM
When: Tuesday, December 2 | 2 p.m. EST
Presenters: Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC | Minnesota Oncology
The treatment landscape for metastatic castration-sensitive prostate cancer (mCSPC) continues to evolve, especially with the expanding role of darolutamide in combination approaches. This session focuses on the clinical insights that influence day-to-day patient management.
We’ll take a closer look at:
- How darolutamide works and why its mechanism matters when selecting therapy
- Pivotal trial findings that define its place in mCSPC, including efficacy and safety considerations
- Where combination therapy with ADT + darolutamide fits now, and how to determine which patients benefit most
- Practical guidance for building individualized treatment plans that align with current guidelines and emerging evidence
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
Upcoming Webinar
Repotrectinib (Augtyro®) in Patients with ROS1 Fusion-Positive NSCLC: Data from the Pivotal Phase 1/2 TRIDENT-1 Trial
December 4, 2025 | 2:00 PM